Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
8,058,320
-
Share change
-
+2,821,053
-
Total reported value
-
$25,937,773
-
Put/Call ratio
-
49%
-
Price per share
-
$3.22
-
Number of holders
-
48
-
Value change
-
+$9,858,727
-
Number of buys
-
34
-
Number of sells
-
10
Institutional Holders of Gain Therapeutics, Inc. - COM (GANX) as of Q4 2025
As of 31 Dec 2025,
Gain Therapeutics, Inc. - COM (GANX) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
8,058,320 shares.
The largest 10 holders included
MARSHALL WACE, LLP, Potomac Capital Management, Inc., JONES FINANCIAL COMPANIES LLLP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, VANGUARD GROUP INC, Cambridge Investment Research Advisors, Inc., DME Capital Management, LP, GEODE CAPITAL MANAGEMENT, LLC, JANE STREET GROUP, LLC, and BlackRock, Inc..
This page lists
48
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.